(IBRX) ImmunityBio, Inc. Business Model Canvas Research

ImmunityBio, Inc. has licensing agreements with 8 counterparties, giving it access to outside intellectual property that can widen its pipeline and speed technology intake. This setup lowers build-from-scratch risk and supports a broader development base across its cancer and immunotherapy work.

• 8 licensing counterparties
• Broader external IP access
• Supports pipeline breadth
• Helps acquire new technology

ImmunityBio’s key partnership base includes licenses from CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and the Infectious Disease Research Institute, giving it access to immunotherapy and infectious-disease know-how across 4 counterparts. These deals expand the company’s technology stack without building every asset in-house.

• 4 licensing counterparts
• Immunotherapy and infectious-disease assets
• Core part of the technology base

ImmunityBio, Inc. runs oncology programs across liquid and solid tumors, with clinical execution centered on bladder, pancreatic, and lung cancers. Its lead bladder program, ANKTIVA, was FDA-approved in April 2024 for BCG-unresponsive NMIBC with CIS, and that commercial and trial work anchors execution in 2025.

• Bladder, pancreatic, lung focus
• Liquid and solid tumors
• Clinical execution is core

ImmunityBio, Inc. also develops vaccines and therapies for infectious diseases, with work that includes SARS-CoV-2 and HIV. That expands Key Activities beyond cancer and gives the Company Name a second pipeline axis that can support later-stage value creation.

• SARS-CoV-2 and HIV programs
• Broadens beyond oncology
• Builds pipeline optionality

ImmunityBio, Inc. depends on its scientific and clinical team because clinical-stage biotech needs deep R and D skill to move from discovery to trials. This human capital drives translational science, clinical development, and the execution of its pipeline.

• Core resource: specialized talent
• Supports discovery to clinic
• Drives translational science

ImmunityBio, Inc. is based in San Diego, California, a major biotech cluster that helps it tap talent, academic links, and lab networks. The city’s life science base includes 1,200+ companies, so the headquarters supports hiring, partnerships, and faster access to research talent.

• San Diego biotech cluster
• Stronger hiring pool
• Better partnership access

ImmunityBio, Inc. covers both liquid and solid tumors, with key programs in bladder, pancreatic, and lung cancers. That widens the addressable base: U.S. estimates include 83,190 bladder, 66,440 pancreatic, and 234,580 lung cancer cases in 2024, supporting broader oncologist reach and more treatment settings.

• Bladder, pancreatic, and lung focus
• Liquid and solid tumor coverage
• Broader physician and patient base

ImmunityBio, Inc. uses pathogen-targeted vaccines for SARS-CoV-2 and HIV to extend its immune platform beyond oncology, giving the Business Model Canvas a second growth lane in high-need infectious disease markets. The value is diversification: two vaccine programs can broaden the pipeline while reusing the same immune-engineering base.

• SARS-CoV-2 and HIV programs
• Extends the immune platform
• Diversifies the oncology pipeline

ImmunityBio, Inc. depends on trial site relationships to run Phase II and Phase III studies, since active sites drive enrollment, patient monitoring, and data capture. In biotech, these sites are a core channel because trial speed and data quality directly shape development timelines and cash use.

• Drives enrollment
• Supports monitoring
• Improves data quality

ImmunityBio, Inc. relies on patient-centered clinical support in late-stage trials because enrolled patients need direct safety checks, follow-up visits, and fast responses to side effects. In multi-site oncology studies, keeping patients engaged is critical; even a small drop in retention can delay completion and readout.

• Direct safety monitoring
• Follow-up to reduce dropouts
• Patient retention drives completion

Business development agreements are a key channel for ImmunityBio, Inc. in biotech partnering. They give external organizations access to assets for co-development and possible commercialization, which can speed trials and widen reach; in biotech, such deals often link research, funding, and go-to-market rights in one contract.

• Direct access to partners
• Co-development of assets
• Possible commercialization rights

Scientific communication is a key channel for ImmunityBio, Inc. because clinical-stage companies use peer-reviewed papers and conference abstracts to show trial data, guide physicians and researchers, and keep investors informed. For ImmunityBio, this matters as its lead asset, ANKTIVA, moved into the market in 2024, so clear data updates help build pipeline credibility.

• Reaches physicians, researchers, investors
• Shares trial data and safety signals
• Builds awareness for the pipeline

ImmunityBio’s key customer segment is oncologists, infectious disease physicians, and trial investigators: they decide treatment use, drive enrollment, and keep protocols on track. In 2025, this matters even more because ANKTIVA is the company’s first FDA-approved product, so physician trust directly affects adoption and follow-on study recruitment.

• Drive patient enrollment
• Shape protocol execution
• Influence future adoption

ImmunityBio also serves pharma and biotech partners through licensing and collaboration, so biotech firms and research institutions act as commercial customers in its platform model. In 2025, this channel matters because it turns the company’s science into repeatable partner use, not just product sales.

• Licensing supports partner adoption
• Collaboration expands platform reach
• Biotech and research groups are key buyers

ImmunityBio, Inc. keeps regulatory submissions and quality systems at the center of clinical development, because each candidate needs FDA-facing work, cGMP controls, and documented compliance. These functions add specialized staff and fixed overhead; in 2025, the Company’s R&D and compliance spend remained a major cash use as it advanced candidates through review.

• FDA submissions

• cGMP quality controls

• Specialized compliance staff

ImmunityBio, Inc.’s general and administrative cost is public-company overhead: corporate, finance, legal, IP, and admin work that keeps the clinical business running. In fiscal 2025, this spend stayed a key cash-use line because the Company had to fund SEC reporting, IP defense, and operating support alongside trials and commercialization.

• Public-company overhead
• Finance, legal, IP, admin
• Supports clinical operations

Royalties can add long-duration upside for ImmunityBio, Inc. if licensed assets reach market, because payments are usually tied to product sales. That means cash flow can scale with partner demand, while ImmunityBio keeps exposure to upside without bearing full launch costs.

In the latest filings, this stream is still prospective, so the key driver is future commercialization timing and sales strength, not current volume. If approved programs scale, royalty income can become a low-capex revenue line that extends well beyond the first launch year.

• Sales-linked cash flow
• Low direct launch cost
• Long-tail upside if approved

Research grants and sponsored contracts can fund ImmunityBio, Inc.’s early and translational programs, especially in disease-focused work where lab-to-clinic costs run high. This revenue stream helps offset R&D spend before product sales, which matters when research and development was $365.7 million in 2024 and still outpaced revenue.

• Funds early and translational research
• Supports disease-specific programs
• Offsets R&D before product sales